BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31323160)

  • 1. Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.
    Ferguson J; Wilcock DJ; McEntegart S; Badrock AP; Levesque M; Dummer R; Wellbrock C; Smith MP
    Pigment Cell Melanoma Res; 2020 Jan; 33(1):74-85. PubMed ID: 31323160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
    Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
    Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
    Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
    Shabna A; Antony J; Vijayakurup V; Saikia M; Liju VB; Retnakumari AP; Amrutha NA; Alex VV; Swetha M; Aiswarya SU; Jannet S; Unni US; Sundaram S; Sherin DR; Anto NP; Bava SV; Chittalakkottu S; Ran S; Anto RJ
    Cell Mol Life Sci; 2022 Aug; 79(9):478. PubMed ID: 35948813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
    Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
    Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
    Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
    Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
    Miskolczi Z; Smith MP; Rowling EJ; Ferguson J; Barriuso J; Wellbrock C
    Oncogene; 2018 Jun; 37(23):3166-3182. PubMed ID: 29545604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX5 is involved in balanced MITF regulation in human melanoma cells.
    Kordaß T; Weber CE; Oswald M; Ast V; Bernhardt M; Novak D; Utikal J; Eichmüller SB; König R
    BMC Med Genomics; 2016 Feb; 9():10. PubMed ID: 26927636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
    Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
    Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.